Crown Bioscience Publishes New Study in PLOS ONE Highlighting the Use of Clinically Relevant 3D In Vitro PDX-Derived Organoid Models as Powerful Tools to Accelerate Cancer Drug Discovery
Crown Bioscience, a global contract research organization (CRO), and JSR Life Sciences company, announced today their newly published study in PLOS ONE, a journal of the Public Library of Science (PLOS), demonstrating the establishment and application of a highly clinically relevant 3D in vitro PDX-derived organoid (PDXO) biobank for higher-throughput screening for cancer drug discovery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230105005843/en/
Rajendra Kumari, PhD, Executive Director of Integrated Solutions at Crown Bioscience (Photo: Business Wire)
This study aligns well with the recent Senate Bill 5002, titled FDA Modernization Act 2.0, introduced in the United States Senate, which authorizes the use of alternatives to animal testing, including cell-based assays for the purposes of drug and biological product applications.
“This invaluable publication demonstrates our ongoing commitment to develop innovative preclinical models for our customers by including the provision of robust and clinically relevant in vitro solutions as early as possible in the drug development process followed with matched translational models downstream,” commented Rajendra Kumari, PhD, Executive Director of Integrated Solutions at Crown Bioscience. “Organoids maintain a high degree of clinical relevance that cannot be achieved with traditional 2D cell lines and other 3D systems. As a result, in vitro drug screening with PDXOs represents a highly physiologically relevant platform that better predicts patient response making these ideal alternatives to animal testing.”
This new study reports on the largest living, commercially available PDXO biobank—with approximately 550 tumor organoid models derived from a collection of matched PDXs representing 17 different types of carcinomas. The main findings of the study include:
- The biological equivalence and interchangeability between PDXOs and parental PDXs were confirmed based on genomics, histopathology, and pharmacology.
- PDXOs in 384-well format assays are reliable, robust, and suitable for higher-throughput screening for rapid identification of drug sensitivity and drug combination strategies, including for matrix screening, encompassing both lead compounds and indications.
- PDXOs are amenable to engineering, such as gene editing to significantly broaden large-scale research applications, including in vitro/in vivo imaging analysis.
- The successful co-culture of PDXOs with PBMCs and CAR-T cells to investigate immune modulation and tumor killing.
This large biobank provides a unique collection of matched in vitro and in vivo preclinical patient-derived models which can be accessed via Crown Bioscience’s online databases OrganoidBase™ and HuBase™. This powerful translational tool has distinct advantages over other systems such as providing higher throughput with faster results as compared to in vivo models alone, with robust and renewable assay performance that reflects reproducibility of other in vitro systems. In vitro drug screening with PDXOs can rapidly be integrated into early drug development and interchangeably with translational studies and improved predictions of clinical outcome.
To read the full publication entitled “A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology”, follow this link.
About Crown Bioscience
Crown Bioscience is a global CRO that provides preclinical and translational platforms to help our customers advance their research and development in oncology, immuno-oncology, and immune-mediated inflammatory diseases (IMID). Crown Bioscience is the exclusive preclinical CRO to offer tumor organoid services, utilizing Hubrecht Organoid Technology (HUB) to establish 3D in vitro tumor organoids that have been shown to faithfully recapitulate the phenotypic and genetic features of their original tumor, and these models are playing an increasingly important role in cancer drug discovery, particularly in identifying anticancer agents with improved translational potential. In addition, Crown Bioscience has developed OrganoidBase™, an extensive searchable biobank consisting of hundreds of PDXO models with information on histopathology, IC50, and genomic and transcriptomic analysis data associated with drug response. Crown Bioscience is focused on helping our customers develop novel therapies to help patients receive the right treatment at the right time. Founded in 2006, Crown Bioscience has ten facilities across the US, Europe, and Asia.
For more information or to get in touch, please visit: www.crownbio.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
More Than Half of Visitors to teamLab Planets in Toyosu, Tokyo Now Come From Overseas. Starting in March, Artworks Featuring Cherry Blossoms That Bloom Across the Space Will Be on View for the Spring Season Only27.1.2023 20:00:00 EET | Press release
Approximately 100,000 people from overseas visited teamLab Planets in Toyosu, Tokyo, between December 9, 2022 and January 9, 2023. (*1) Of the visitors across one month, around 60% , or 1 in 2 visitors, were non-residents visiting Japan (*1), and the number of visitors from overseas has tripled compared to the same month in 2019 (before COVID-19). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230126005440/en/ teamLab, Floating in the Falling Universe of Flowers © teamLab Furthermore, according to a survey conducted by the museum, about 70% of the visitors from overseas knew about the museum before considering their trip to Japan, and there was a trend of the museum being one of the main purposes to visit Tokyo. (*2) *1 From the official website tickets purchaser data (survey period: December 9, 2022 - January 9, 2023) *2 From the visitor survey data (survey period: December 17, 2022 - January 10, 2023) We will continue to p
Global Processing Services Appoints Former Visa Executive Jim McCarthy to Lead Global Sales and Product27.1.2023 13:01:00 EET | Press release
Global Processing Services (“GPS”), a fast-growing next-gen global payments technology platform, today announced the appointment of Jim McCarthy as Executive Vice President – Global Head of Sales and Product, and Kevin Fox as the company’s new Chief Revenue Officer. In this newly created role, Jim will lead GPS’ global commercial and product teams in close collaboration with Kevin on sales acceleration. Jim is a highly accomplished payments veteran with over 30 years of experience, including 18 years at Visa where he held senior roles in sales, risk and authentication, consumer credit, digital products and product innovation. As Visa’s EVP of Innovation and Strategic Partnerships, Jim was responsible for the development of Visa’s product and technology roadmap, innovation efforts, and led business development for strategic partnerships. While at Visa he was responsible for the introduction of 3D Secure and Visa Token Service, which have become industry standards, and also contributed t
Major Landowner Federations to Support AMR Against Nordic Mining ASA (NOM) in the Norwegian Supreme Court27.1.2023 12:59:00 EET | Press release
Key landowner federations declare 3rd party intervention in support of Arctic Mineral Resources’ appeal to the Supreme Court in the case against Nordic Rutile AS (NRU), a wholly owned subsidiary of Nordic Mining ASA (NOM). Arnold Rørholt, lawyer and AMR’s Chairman, welcomes the 3rd party intervention in favour of AMR: “The intervention will ensure that the Supreme Court, as opposed to the courts of lower instance, appreciates the principal nature of the case and the Constitutional issues underpinning it, and interprets the Mineral Act in light of these – to the favour of AMR.” “The Western part of the Engebø garnet and rutile province contains around half of the proven reserves in the Engebø deposit, as well as a majority of inferred resources and will support a highly profitable 50 years plus fully underground mining project without a need for deposits on land or in the sea” continues Rørholt. Arctic Mineral Resources (AMR) and the federations argue that the two mineral categories – o
Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.27.1.2023 09:00:00 EET | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended not to grant marketing authorization for investigational palovarotene as a treatment for the ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP). In the E.U. there are currently only symptomatic treatments for FOP, which do not reduce the formation of extra-skeletal bone in patients with the condition. Ipsen will be requesting a re-examination of the CHMP opinion, based on scientific data available from the existing palovarotene clinical trial program. FOP causes permanent and continuous new bone formation in soft and connective tissues, like muscles, tendons and ligaments, a process known as heterotopic ossification (HO).1 Once formed, it is irreversible.1 The average age of diagnosis is 5 years old2 and ultimately FOP shortens the median life expectancy to 56 years as untimely death is
Green Steel Technology Company Boston Metal Announces $120M Series C Financing Led by ArcelorMittal27.1.2023 08:01:00 EET | Press release
Boston Metal, a company developing technology to fully decarbonize steel production, today announced the $120 million first close of Series C fundraising led by multinational steel company, ArcelorMittal S.A. (NYSE: MT). Microsoft's Climate Innovation Fund and SiteGround Capital also joined as new investors in this round, alongside current investors. ArcelorMittal’s lead investment was made through its XCarb® Innovation Fund. Commenting, Aditya Mittal, CEO, ArcelorMittal, said, “In Boston Metal, we are investing in a team that has made impressive progress over a relatively short period of time, developing a technology that has exciting potential to revolutionize steelmaking. In our extensive discussions with them, we have been impressed by the passion and vision they have to contribute to the decarbonization of steelmaking. They are an exciting and welcome addition to the XCarb® Innovation Fund’s portfolio.” Boston Metal’s patented Molten Oxide Electrolysis (MOE) process is being comme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom